Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Methylphenidate controlled release - Purdue Pharma

Next Previous
Drug Profile

Methylphenidate controlled release - Purdue Pharma

Alternative Names: Adhansia XR; Aptensio XR; Biphentin Capsules; FOQUEST; Methylphenidate ER; Methylphenidate extended release; PRC-063

Latest Information Update: 05 Apr 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Purdue Pharma
  • Developer Purdue Pharma; Rhodes Pharmaceuticals; Universite Laval
  • Class Behavioural disorder therapies; Neuroprotectants; Nootropics; Phenylacetates; Piperidines; Sleep disorder therapies; Small molecules
  • Mechanism of Action Adrenergic uptake inhibitors; Central nervous system stimulants; Dopamine uptake inhibitors; Monoamine oxidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Attention-deficit hyperactivity disorder
  • Phase II Cognition disorders

Most Recent Events

  • 01 Jul 2021 US FDA approves sNDA application for Methylphenidate controlled release (Adhansia XR®) to update the prescribing information for Attention deficit hyperactivity disorder
  • 14 Jun 2021 Updated efficacy and adverse events data from a phase III trial in Attention-deficit hyperactivity disorder released by Adlon Therapeutics
  • 18 Nov 2020 Efficacy and adverse events data from a phase II trial in Attention-Deficit/Hyperactivity Disorder (ADHD) released by Adlon Therapeutics
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top